Recently, Nanjing Xinbai announced that the company's issue of shares to acquire Shiding Hong Kong and to raise matching funds was approved by the M&A and restructuring review committee of the listed company of the China Securities Regulatory Commission. Specifically, Nanjing Xinbai will be priced at 33.11 yuan. The controlling shareholder Sanpower Group issued 180 million shares to acquire its 100% equity interest in Shiding Hong Kong from the controlling shareholder Sancell Group for 5.966 billion yuan, while the main operating assets of Shiding Hong Kong are US biopharmaceutical companies. Dendreon, which means that Nanjing Xinbai will successfully receive the first FDA-approved Provenge, the only cell immunotherapy drug approved by the US FDA. At the end of June 2017, Sanpower Group completed the acquisition of Dendreon with a consideration of US$819.9 million, the purchase price of US$819.9 million, plus the intermediary fees and financial expenses of the acquisition, and the transfer of RMB 5.968 billion. For Nanjing Xinbai, Sanpower Group put Dendreon into the listed company almost at a low price. In the field of tumor immunotherapy, cellular immunotherapy has become a hot spot in recent years. Among them, dendritic cell tumor immunotherapy and CAR-T are the two most popular tumor cell immunotherapy methods. Dendreon, its core product, Provenge, is a "revolutionary" product in dendritic cell tumor immunotherapy. According to public information, Dendreon Biomedical Company is taught by Stanford University Edgar G. Founded in 1992 by Engleman and Samuel Strober, the company spent billions of dollars on research and development, revealing the clinical safety and efficacy of Provenge, a cellular immunotherapeutic drug for prostate cancer. In April 2010, the US FDA officially approved Provenge for the treatment of metastatic castration-resistant (hormone-refractory) prostate cancer (mCRPC). Relevant clinical data showed that patients who used Provenge survived after three years. More than 37.8% of patients use Provenge. Currently, Provenge is priced at US$93,000 per treatment in the United States. More than 20,000 prostate cancer patients have received Pleevec treatment since the market. Its safety and clinical efficacy are further fully certified. Due to its efficacy and safety advantages, Provenge has been recommended as the first-line treatment for mCRPC by the NCCN Guidelines and has been included in the coverage of major US health insurance coverage. . According to the plan disclosed before the Nanjing Xinbai acquisition, Provenge is the only drug still sold in the market today by Dendreon. Its revenue in the first three quarters of 2017 was 1.774 billion yuan and its net profit was 368 million. yuan. Prostate cancer has become one of the common malignant tumors in men. According to the American Cancer Institute, the incidence of prostate cancer ranks first in American male tumors, accounting for 33% of male malignant tumors, and the incidence rate in China is also generally rising. trend. Therefore, Plewe, as the only cell immunotherapy drug for the treatment of advanced prostate cancer, is of great significance to Nanjing Xinbai. Nanjing Xinbai has previously said that through this acquisition, listed companies can use the brand of Pleway. Effect, entering the US and China's cellular immunotherapy field, the company will have international leading tumor cell immune products and FDA-compliant production processes, combined with Dendreon's research and development experience, production capacity and market experience of many years of listing, listed companies are expected to build A broad cell therapy platform to strengthen the development of listed companies in the field of medical care. At present, Pleway has not yet entered the Chinese mainland market, but Dendreon has built a laboratory in Hong Kong and is expected to enter the Hong Kong and mainland markets. The nursing pad is a kind of disposable sanitary articles made of PE film, non-woven cloth, nap pulp, macromolecule and other materials, which is mainly used for hospital operation, gynecological examination, maternity care, infant care, paralyzed people urinate incontinence, and women during menstruation. Under Pad,Disposable Pads,Reusable Underpad,Disposable Underpad For Incontinence Shandong Kangshun Daily Products Co., Ltd , https://www.centurybenifit.com
The nursing pad is not a diaper.The product is mainly composed of non-woven cloth, villous pulp, polymer and PE film.